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Abstract
Background: Prion infection results in progressive neurodegeneration of the central nervous
system invariably resulting in death. The pathological effects of prion diseases in the brain are
morphologically well defined, such as gliosis, vacuolation, and the accumulation of disease-specific
protease-resistant prion protein (PrPSc). However, the underlying molecular events that lead to the
death of neurons are poorly characterised.
Results: In this study cDNA microarrays were used to profile gene expression changes in the
brains of two different strains of mice infected with three strains of mouse-adapted scrapie.
Extensive data was collected and analyzed, from which we identified a core group of 349 prion-
related genes (PRGs) that consistently showed altered expression in mouse models. Gene ontology
analysis assigned many of the up-regulated genes to functional groups associated with one of the
primary neuropathological features of prion diseases, astrocytosis and gliosis; protein synthesis,
inflammation, cell proliferation and lipid metabolism. Using a computational tool, Ingenuity Pathway
Analysis (IPA), we were able to build networks of interacting genes from the PRG list. The
regulatory cytokine TGFB1, involved in modulating the inflammatory response, was identified as
the outstanding interaction partner for many of the PRGs. The majority of genes expressed in
neurons were down-regulated; a number of these were involved in regulatory pathways including
synapse function, calcium signalling, long-term potentiation and ERK/MAPK signalling. Two down-
regulated genes coding for the transcription regulators, EGR1 and CREB1, were also identified as
central to interacting networks of genes; these factors are often used as markers of neuronal
activity and their deregulation could be key to loss of neuronal function.
Conclusion: These data provides a comprehensive list of genes that are consistently differentially
expressed in multiple scrapie infected mouse models. Building networks of interactions between
these genes provides a means to understand the complex interplay in the brain during
neurodegeneration. Resolving the key regulatory and signaling events that underlie prion
pathogenesis will provide targets for the design of novel therapies and the elucidation of
biomarkers.
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Background
Prion diseases or transmissible spongiform encephalopa-
thies (TSEs) have long incubation times and are character-
ized by progressive neurodegeneration leading to death
[1]. Brain tissue adopts a spongy appearance and a modi-
fied form of a normal host protein, the prion protein, is
deposited. It is this conformational isomer of prion pro-
tein (PrPSc) that is believed to be the infectious agent. The
progressive neurodegeneration resulting from infection
with prion agents involves diverse cell types, a variety of
cellular interactions, and multiple genes. Genomic and
proteomic techniques can be used to measure the relative
abundance of messenger RNA transcripts and proteins in
cells and tissues. The differential expression of these mol-
ecules between normal and diseased tissues provides
information that can be used to determine the precise
molecular mechanisms involved in neurodegeneration in
prion disease.
A number of studies to determine the gene expression
changes that accompany prion diseases have been per-
formed in different laboratories, including our own [2-9].
Hundreds of differentially expressed genes in various
models of TSEs have been identified; many repeatedly. In
the present study we have performed an extensive global
analysis of gene expression in two strains of mice infected
with three strains of scrapie, to create a list of genes con-
sistently deregulated in multiple scrapie models. This
gene list includes many previously described, as well as a
number of novel genes. Comprehensive bioinformatics
analysis of these data has allowed us to make substantial
progress in defining networks of interacting genes which
operate during neurodegeneration in mouse scrapie.
Results and discussion
Identification of consistently deregulated genes in mouse 
prion disease
C57BL/6 mice were inoculated by intracerebral infection
of brain homogenate from mice clinically infected with
the ME7, 79a and 22A strains of scrapie. In addition VM
mice were also inoculated with the 22A scrapie strain.
Mice were sacrificed at the onset of clinical diseases as
manifested by uncoordinated gait, flaccid paralysis of the
hind limbs, rigidity and abolishment of the righting
reflex. Brain tissue was collected from these mice and the
RNA isolated. Mouse CNS gene expression was analysed
by two-colour microarray experiments using an in house
manufactured 11 K mouse cDNA microarray [2]. RNA
from individual infected mice was hybridized to each
array versus pooled reference RNA from an equivalent
number of age-matched, mock-infected control mice. In
total we hybridized 34 different samples to microarrays in
this experiment; 8–10 individual mice from each of the
four sample groups were individually processed for sepa-
rate microarrays. Hierarchical clustering shows that the
patterns of gene expression are for the most part common
to the different mouse models (Additional file 1). We
used the program EDGE to identify genes that were differ-
entially expressed in mouse brain during clinical disease
[9]. We used a P value cut-off of 0.05 as the criteria for
selection of significantly differentially expressed genes.
In our previous study we found very few genes to be sig-
nificantly differentially expressed during pre-clinical dis-
ease and so in this study we limited analysis to those genes
that were up- or down-regulated at the late clinical stage
of the disease [2]. The resulting gene lists contained
between 917 and 1076 significant genes from each sam-
ple group tested; a sample group contained 8–10 individ-
ual infected mice and equal numbers of age matched,
mock-infected control mice. These lists of significant
genes were used to compile a master list of genes based on
the criteria that significant differential expression was
identified in at least three of the experimental sample
groups tested. The 349 genes that selected were termed
"prion-related genes" (PRGs); a complete list of these dif-
ferentially expressed genes including annotation is pro-
vided as Additional File 2. This list of genes includes many
that have been previously identified as deregulated in
neurodegenerative diseases, these genes are marked on
the table; a number of novel genes were also identified.
We confirmed deregulation of ~50% of the 349 PRG's
(marked in bold in Additional File 2) to be accordingly
deregulated in a fourth strain of scrapie, RML, using whole
genome mouse arrays purchased from Agilent.
We used an online tool based on a curated database, the
Ingenuity Pathways Knowledge Base (IPKB), to annotate
genes and to determine potential regulatory networks and
pathways. The IPKB contains information on human,
mouse, and rat genes including annotations, synonyms
and over 1.4 million published biological interactions
between genes, proteins and drugs. This database is con-
tinually updated and supplemented with curated relation-
ships taken from MEDLINE abstracts; i.e. each gene
interaction held in the IPKB is supported by published
information. Thus, the IPKB thus provides a framework by
which lists of genes identified by large-scale microarray
studies can be annotated in terms of their functional rela-
tionships, and those that have been shown to interact.
We first identified key biological functions and/or dis-
eases that contain a disproportionately high number of
genes from the PRG list in relation to the assayed gene
population as a whole; the assayed gene group is the total
genelist from the microarray used. Representative catego-
ries of biological functions and/or diseases in which PRG
genes are over-represented (P values < 0.001) are provided
in Table 1. This list of genes includes members of gene
families that have been identified in previous studiesBMC Genomics 2008, 9:114 http://www.biomedcentral.com/1471-2164/9/114
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including genes involved in; lysosome organization and
biogenesis, immune cell activation and inflammatory
response, lipid metabolism, apoptosis, protein biosynthe-
sis and proteolysis, nervous system function and synaptic
transmission, and cytoskeleton organization and biogen-
esis.
Identification of biologically relevant networks
To further investigate the global expression response to
infection with the prion agent, and to define how individ-
ual regulated genes interact to have a coordinated role in
specific pathways, we identified potential networks of
interacting PRG's using the Ingenuity Pathway Analysis
tool. The methodology integrates genomic data with min-
ing techniques to predict protein networks that comprise
protein-protein interactions and other functional link-
ages. Each potential network is given a score, which is a
probabilistic fit between the networks and a list of biolog-
ical functions stored in the IPKB. The score takes into
account the number of Focus genes (from the PRG list) in
the network, and the size of the network, to approximate
how relevant it is to the original list of genes; these scores
are used to rank the networks. As the list was extensive we
restricted our analysis to those networks that had scores
>9 (a score of 3 or greater was considered significant (p <
0.001). We identified 22 networks of potentially interact-
ing genes from amongst the PRGs; the top 5 networks are
provided in Table 2.
The two highest ranked networks are provided as Figures
1 and 2; each contain 35 PRG's with very strong evidence
of connectivity between the genes. The biological func-
tions and/or diseases that were most significant to the
genes found in each network were identified. The top
ranked network identified by IPA (Figure 1A) is associated
with tissue development, specifically the determination of
the quantity of cells, particularly phagocytes, and in bio-
logical processes controlling cell death and survival. Strik-
ingly, network 1 consists of genes that almost all interact
directly with transforming growth factor (TGF)-beta 1.
The up-regulation of TGF-beta 1 was confirmed by RT-
PCR (Figure 2A). TGF-beta 1 is a multifunctional cytokine
that is a potent regulator of injury and inflammatory
responses in the central nervous system and has been
implicated in cerebral amyloid deposition and pathogen-
esis of neurodegenerative diseases, including prion dis-
eases [10-13]. TGF-beta 1 expression has been previously
reported to increase throughout prion disease concomi-
tant with astrocytes and microglial accumulation [14,15].
Indeed, TGF-beta1 is largely produced in astrocytes and
microglia but can be expressed in neurons. Over expres-
sion of TGF-beta1 in astrocytes protects adult mice against
neurodegeneration during acute, excitotoxic and chronic
injury [16], its loss leads to increased neuronal cell death
and gliosis [17,18]. Its role during prion induced neuro-
degeneration is likely to be to suppress inflammation in
the brain that could exacerbate the course of the disease.
Network 2 (Figure 1B) contains genes that are primarily
involved in nervous system function. The major biologi-
cal functions of genes in this network are learning and
behaviour (SGK, PTN, SDC3, CREB1, EPB41), neuronal
migration and outgrowth of neurites (NF2, PRKCE,
FGFR3, GJA1, CREB1, PTN, PTPRZ1, SST) and cell cycle
progression (SST, CTNNB1, TF, PKD1, TOB2). The genes
in this network may play a role in the loss of function and
Table 1: Summary of the highest represented functional groups of genes from the PRG list. Up-regulated genes are in bold type, down-
regulated genes in italics.
Top Biological Functions Genes
Lipid Metabolism PRDX6, HEXB, APOD, OSBP, BMPR1B, PTPMT1, LTC4S, DHCR24, APOE, SGPP1, 
PITPNC1, HMGCS2, OSBPL1A, GRN, CYP46A1, ABCA1
Nervous system function and synaptic transmission MBP, PMP22, PLP1, CBLN1, APOE, CHRNB4, YWHAG, CART, MAL, VAMP1, VAMP2, SYT2, 
SYN2, SNPH, RPH3A, CAMK2A, SEPT, CTNNB1, DNER, THY1, CD9, RTN4, NRXN1, 
NRXN2, PTN
Cytoskeleton organization and biogenesis SGCB, APOE, TMSB4X, THY1, CAPZB, RHOF, LASP1, CNN3, ARPC3, YWHAG, 
TLN1, TUBB2A, ERBB2IP, DCTN2, MYL6, GFAP, MAP1LC3B, ALS2CR2, NEFL, MYH11, 
EPB49
Protein biosynthesis and folding RPL11, RPS3, RPS27, FAU, RPS9, WBSCR1, SECISBP2, RPL9, EEF1A1, RPL24, 
RPL26, CCT6A, ERP29, HSPB3, PPIL2, CRYAB, DNAJA1, WBSCR18, HSPA9B, HSP90AB1
Lysosome, organization and biogenesis LAPTM5, CTSS, PRDX6, MCOLN1, PPT1, CTSB, LAMP2, HEXB, CTSK, CTSH
Proteolysis UCHL5, SNX17, PSMA3, CTSS, SHFM1, ASRGL1, CTSB, PGCP, CTSK, CTSH, 
MMP14
Apoptosis APOE, CTSB, LY86, SGK, HIPK2, MAL, NFKB1A, PPM1F, APLP1, TRAF5, CLU, 
CTNNB1, PRKCE, TIMM50, ALS2CR2, SOX9, DDIT3, TM2D1, SGPP1, THY1, TNF, 
SPP1, YWHAG, RTN4, TGFB1, HSPA9B
Immune cell activation and inflammatory response EGR1, THY1, TGFB1, SPP1, IGBP1, PRKCD, CBLB, LY86BMC Genomics 2008, 9:114 http://www.biomedcentral.com/1471-2164/9/114
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eventual death of neurons that underlies the irreversible
pathogenesis of prion induced neurodegenerative dis-
eases.
As in network 1 this network also contains a central gene,
CTNNB1 that interacts in some way with a large propor-
tion of the other network genes. The small but consistent
up-regulation of CTNNB1 was confirmed by RT-PCR, Fig-
ure 2B. This gene is a phosphoprotein involved in Wnt sig-
naling and is an important mediator of cell survival, but
has previously not been shown to have a role in prion dis-
eases.
Other up-regulated CTNNB1 interacting genes in this net-
work are SGK, PTN, PTPRZ1 and SDC3. SGK is a serine/
threonine kinase, serum and glucocorticoid-regulated
kinase 1, which is up-regulated in response to various
external stimuli and a number of neurological diseases
including. SGK appears to be ubiquitously up-regulated in
the brain in response to a strong stress signal and may
have a neuroprotective effect like CTNNB1 which is grad-
ually overridden by deleterious mechanisms during the
disease process [19]. PTPRZ1 and SDC3 are both receptors
expressed on neurons; significantly they share the same
ligand, the heparin-binding growth factor PTN, which is
also an up-regulated PRG suggesting. Although PTN is
known to stimulate neuron and astrocyte differentiation
[20,21] the receptors PTPRZ1 and SDC3 are primarily
expressed only on neurons. PTN has also been shown to
be up-regulated in response to cell stress [22] and to have
a neuroprotective role in some instances [23].
Prediction of cell-specific regulation of PRG's
One of the major pathological features of prion diseases is
astrocytosis. As our results were obtained with whole
brain tissue it is likely that many deregulated genes were
of astrocytic/microglial origins. To give a more complete
picture and greater accuracy in the identification of spe-
Table 2: List of Ingenuity networks generated by mapping the focus genes (PRGs) that were differentially expressed during 
neurodegeneration.
Network genes (focus genes in bold) Score# Focus Genes Top Functions
1 ALPL, CALM2, CLU, CNN3, CTSK, EEF1A1, 
EGR1, G3BP, GFRA2, GORASP2, GTF2I, 
HSPA9B(includesEG:3313), KLF16, KRT1, 
TC4S, MMP14, MYH11, MYL6, P4HA1, PDGFC, 
PGCP, PGRMC1, PRKCD, PRKCG, PSMA3, 
RAB1A, RAP1A, RET, SGPP1, SLC7A1, 
SMAD5, TBCD, TGFB1, TUBB2A, WBSCR1
52 35 Tissue Development, Cell Death, Endocrine System
2 ACTB, APOD, BTF3, CAPZB, CASK, 
CASKIN1, CCT6A, CREB1, CTNNB1, DBI, 
EPB41, ERBB2IP, ERP29, FGFR3, GJA1, 
GTF2F1, GTF2H1, HSP90AB1, ID4, 
LRRFIP2(includesEG:9209), NF2, NRXN1, 
PKD1, PRKCE, PTN, PTPRZ1, SDC3, SFRS1, 
SGK, SLC9A3R1, SST, TF, TNRC6A, TOB2, 
TRPC4
52 35 Behavior, Cellular Movement, Cell Cycle
3 APOE, B2M, CEBPD, CTSB, CTSS, HEXB, HLA-
DMA, HLA-F, HMGCS2, HRSP12, IFNG, IL6, IL17A, 
IL1RL1, ITGB3, LAPTM4A, LY86, MCHR1, 
MLYCD, NR1D1, NR1H2, OSBPL1A, PLA2G5, 
POLR2D, POLR2F, POLR2G, POLR2I, POLR2J, 
POLR2K, POMP (includesEG:51371), RXRA, 
SLC37A4, TAP1, TLN1, ZMYND
19 19 Inflammatory Disease, Connective Tissue Disorders, 
Infectious Disease
4 ACTB, ALB, ATOX1, BID, CASP4, CEBPD, 
CLCN2, CLU, CST3, CTSB, CTSH, CTSS, 
DCTN2, DDIT3, DEFB103A, 
DEFB4(includesEG:1673), FKBP4, GFAP, GH1, 
GLUD1, GTPBP4, IRF1, MLLT4, NCKIPSD, 
NRXN2, SLPI, SNPH, TANK, TINF2, TP53, 
XRCC5, XRCC6, YWHAA, YWHAB, YWHAG
17 18 Cancer, Cell Death, Tumor Morphology
5 A2M, ALB, APBB3, APLP1(includesEG:333), 
APOA1, APOE, APP, ARPC3, CEBPD, CLU, 
CREB1, CST3, CTSD, DAB1, DOCK3, DPYSL2, 
FOXA1, FOXA2, FOXA3, HIP2, HMOX1, HSPG2 
(includesEG:3339), LIF, MAPT, ONECUT1, PAX3, 
PTGS2, RAB11B, RASA2, RLBP1, SPON1, SYT2, 
THBS3, TM2D1, TTR
16 17 Cellular Assembly and Organization, Neurological Disease, 
Tissue Morphology
* Genes in BOLD type are those mapped by the significant genes. # A score of 3 or greater was considered significant (p < 0.001)BMC Genomics 2008, 9:114 http://www.biomedcentral.com/1471-2164/9/114
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Pathway analysis based on the Ingenuity Pathway Knowledge Base (IPKB) Figure 1
Pathway analysis based on the Ingenuity Pathway Knowledge Base (IPKB). The two highest scoring networks from the PRG list 
are shown. The shaded notes are genes from among the PRG list; colour shading corresponds to the type of deregulation, red 
for up-regulated genes, and green for down-regulated. White open nodes are not from among the 349 PRG list genes but are 
transcription factors that are associated with the regulation of some of these genes identified by IPKB. The shape of the node 
indicates the major function of the protein. A line denotes binding of the products of the two genes while a line with an arrow 
denotes 'acts on'. A dotted line denotes an indirect interaction and the orange lines indicate potential interaction with those 
transcription factors added by IPA that are not on the PRG list.
A) 
B)                                                                                             BMC Genomics 2008, 9:114 http://www.biomedcentral.com/1471-2164/9/114
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cific pathways involved in prion pathogenesis, we anno-
tated the PRG list based on information on the specific
cellular location of the expression of individual genes. To
do this we used data from various sources including pub-
lished microarray studies, PubMed searches and an online
in situ hybridization database, the Allen Brain Atlas (ABA)
[24]. This resulted in the basic annotation of the PRG list
in terms of the cell-type; in this case astrocytes/microglia
versus neurons. Especially useful was a recent genomic
study that identified distinctive transcriptional profiles in
astrocytes from in vitro model systems as well as primary
astrocytes; these experiments produced a list of 85 astro-
cyte-specific candidate genes [25]. Comparison of this list
with our PRG list revealed that at least one third of these
genes were amongst the up-regulated PRG. We used this
list, plus further gene expression data from a study by
Ponomarev et al [26] to compile a list of 61 genes, PRG-A,
that we concluded to be exclusively or predominantly
expressed in astrocytes or microglia. These genes are pro-
vided in Additional File 3. The remainder of the PRG list
was named PRG-N and contained some genes known to
be expressed in neurons, due to incomplete annotation;
however, it is likely that some genes in this list may be
expressed in other cell types within the CNS.
We analyzed the PRG-A and PRG-N lists in isolation to
reveal the most significant biological processes/diseases
associated with these sub-groups of genes. Not surpris-
ingly, the PRG-A list contained genes primarily involved
in cellular proliferation and growth, cellular migration
and inflammatory disease, accurately reflecting the prolif-
eration, activation, and migration of astrocytes and glial
cells to damaged areas of the brain. The most significant
network is provided in Figure 3, all the PRGs are up-regu-
lated.
Another highly represented group of genes from this list
(12/61) have an association with lipid metabolism and
transport as annotated in the IPA Knowledge Base data-
base; APOD, APOE, ABCA1, CTSS, TNF, IL1A, MBP, PLP1,
PRDX6, CLU, CEBPD, TGFB1. A disruption in lipid
metabolism and signaling is one of the early alterations
apparent in many neurodegenerative diseases, including
prion diseases [27,9]. This group includes some of the
most up-regulated PRG genes identified in the study
including APOE, APOD and ABCA1 involved in the trans-
port of cholesterol. Neurons require APOE-cholesterol to
develop synapses in vitro; APOE-cholesterol synthesis
occurs mainly in glial cells and is secreted in a process
involving ABCA1, a cholesterol efflux pump in the cellular
lipid removal pathway. Neurons pick up cholesterol via
an LDL receptor. Interestingly, three genes from the PRG-
N list were also involved in lipid biosynthesis, specifically
cholesterol catabolism, and are down-regulated in our
mouse models; DHCR24, HMGCS2 and CYP46A. These
genes previously been reported to have an association
with Alzheimer's disease [28]. Deregulation of lipid
homeostasis, particularly a cholesterol turnover in the
CNS, is a feature common to neurodegenerative diseases
including prion disease. Indeed cholesterol metabolites
are targets of a number of recent studies aimed at the iden-
tification of early biomarkers for neurodegenerative dis-
eases [29].
A number of mechanisms for neuronal cell death during
prion disease have been suggested including the direct
toxicity of PrPSc and mechanisms in which the normal cel-
lular function of PrPC is subverted resulting the triggering
of pathways that lead to cell death [30]. In either case it is
vital to determine the specific cell death pathways in
affected neurons in order to fully understand the disease
process and develop drugs that promote neuronal sur-
vival. We next used the Ingenuity Pathway Analysis tool to
identify biological networks and cellular functions that
Validation of microarray data by real-time PCR Figure 2
Validation of microarray data by real-time PCR. The levels of 
expression in two different models of scrapie infected mice 
(RML/C57BL6 and VM/22A) were measured for two genes 
(A) TGFB1 and (B) CTNNB1. Expression levels were meas-
ured in three individual mice by direct comparison with that 
from pooled RNA isolated from 3 age-matched, mock-
infected, control mice performed in triplicate.
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were most significant to the PRG-N list. The top-ranked
pathway is shown in Figure 4 and contains largely down-
regulated genes. The most affected biological processes
were molecular transport and protein trafficking, regula-
tion of gene expression, cellular movement and cell sig-
nalling. Additionally a number of signalling pathways, in
particular those involved in synaptic long term potentia-
tion, calcium signalling, and the ERK/MAPK signalling
pathway were significantly over represented (p < 0.001) in
this group of genes, Figure 5.
All of these pathways have previously been reported to
contribute to neuronal death in prion diseases. Abnor-
malities in synaptic plasticity are believed to be one of the
Pathway analysis based on the Ingenuity Pathway Knowledge Base (IPKB) Figure 3
Pathway analysis based on the Ingenuity Pathway Knowledge Base (IPKB). The highest scoring network from the PRG-A list is 
shown. Annotation is as described for Figure 1.BMC Genomics 2008, 9:114 http://www.biomedcentral.com/1471-2164/9/114
Page 8 of 14
(page number not for citation purposes)
earliest features of prion disease, detectable at about the
same time as the deposition of PrPSc, although there are
conflicting reports as to the specific electrophysiological
changes that take place [31,32]. Significantly, data from
many of these electrophysiologic, and Ca2+ measurement
studies in neurons converge to suggest that the recruit-
ment of PrPC into prions leads to compromised Ca2+
homeostasis [33-35]. Additionally, these studies, as well
as a number of other genomic studies, strongly implicate
calcium homeostasis as a biological process that is dereg-
ulated in prion diseased brain. We cannot determine from
this data whether synapse dysfunction, and alterations in
calcium signalling are a cause or effect of neuronal death
in prion disease. However, it is known that synaptic dys-
Ingenuity Network analysis showing interactions between PRGs from the PRG-N list, i.e. those genes predominantly expressed  non-astrocyte/microglia CNS cells Figure 4
Ingenuity Network analysis showing interactions between PRGs from the PRG-N list, i.e. those genes predominantly expressed 
non-astrocyte/microglia CNS cells. Annotation is as described for Figure 1.BMC Genomics 2008, 9:114 http://www.biomedcentral.com/1471-2164/9/114
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function can render neurons vulnerable to excitotoxicity
and apoptosis by a mechanism involving disruption of
cellular calcium homeostasis.
In total, 11 genes from the Ingenuity ERK/MAPK signaling
pathway were found to be over represented amongst the
PRG-N genes; CREB1, H3F3B, PPP2R4, PRKAR1A,
PRKCD, PRKCE, PRKCG, RAP1A, TLN1, YWHAB,
YWHAG. The ERK/MAPK pathway is stimulated by vari-
ous growth factors and extracellular stimuli and plays an
important role in transducing stress-related signals in
eukaryotic cells and promoting differentiation and sur-
vival of neuronal cells. A number of previous reports have
provided evidence that the deregulation of MAPK path-
ways play an active role in disease pathogenesis, possibly
by upsetting the balance of intracellular signaling in neu-
rons [36,37]. Indeed, major targets of the MAPK pathway
are the closely related immediate early genes CREB and
EGR1, which are down-regulated PRGs. Both of these
genes code for transcriptional regulators known to be
phosphorylated during neural activity that leads to long-
term synaptic plasticity [38,39] and are thus used as mark-
ers of neural activity [40,41]. Previous studies have linked
decline in the expression of CREB to a progressive increase
of apoptosis [42], and in one study the disruption of
CREB1 expression in mouse forebrain, resulted in pro-
gressive neurodegeneration in the hippocampus and in
the dorsolateral striatum [43]. CREB has also been shown
to share a disproportionate number of transcriptional tar-
gets with the other down-regulated IEG, EGR1 [44]. EGR1
is one of the most consistently down-regulated PRG genes
that we detected in this study; we confirmed its expression
in a number of models of mouse scrapie by quantitative
RT-PCR at both clinical of infection (Figure 6). There is
evidence to suggest that both CREB and EGR are activated
by phosphorylation in prion disease [45,46]. This seem-
ingly contrasts with our finding of down-regulation of
gene expression; however, sustained activation of regula-
tory proteins by phosphorylation is often followed by a
reduction of gene expression as a mechanism of feedback
regulation. Indeed a number of studies have shown that
EGR1 is involved in regulation of the MAPK pathway as
part of a negative feed back loop; activation of the ERK/
MAPK induces active EGR1 which in term transcribes
cdk5/p35, that is able to "switch off" the signaling cascade
[36,37].
Four of the deregulated genes are activators of the ERK/
MAPK signaling pathway; PRKCG, PRKCE, PRKCD and
PRKAR1A. All of these genes are down-regulated apart
from PRKCD, and three of the four kinases belong to the
same family, protein kinase C (PKC). Different PKC iso-
forms can have opposing roles in particular signaling
pathways and can act as sensors mediating either pro- or
anti-apoptotic outcomes to different stimuli [47]. PKRCD
is a key mediator of apoptosis, and its up-regulation dur-
ing prion diseases suggests that this PKC isoform may
have a role in prion pathogenesis either in gliosis or apop-
tosis of neurons. Indeed, a number of studies have shown
that a damaging insult to brain tissue is able to induce the
PRKCD gene in cells such as cortical neurons, astrocytes
and in microglia, in which it is not present under physio-
logical conditions [48].
A summary of the results from this study showing the
genes, pathways and biological processes that characterize
the key molecular events in clinically prion infected
mouse brain is provided as a schematic in Figure 7.
Validation of the level of expression of EGR1 by real-time  PCR Figure 6
Validation of the level of expression of EGR1 by real-time 
PCR. The levels of expression in four different models of 
scrapie infected mice (ME7/C57BL6, 79A/C57BL6, 22A/
C57BL6, 22A/VM) were measured. In each case the expres-
sion levels were measured in three individual mice by direct 
comparison with that from pooled RNA isolated from 3 age-
matched, mock-infected, control mice performed in tripli-
cate.
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Conclusion
Microarray experiments have been performed on tissues
affected by many diverse diseases in efforts to document
the changes in tissues at the transcriptional level. The
majority of such studies generally result in the identifica-
tion of hundreds of genes that are involved in many dif-
ferent biological processes and pathways. In essence most
of these studies provide a very broad overview of tran-
scription in the tissues involved in disease pathogenesis,
with little structured information on the specific processes
and pathways occurring in individual cells. In this study
we used DNA microarray analysis to identify genes that
are consistently differentially expressed in multiple
scrapie infected mouse models. We went further than our
previous study by including data from a number of differ-
ent models of mouse-adapted scrapie. The large numbers
of mice used in the study, and the variety of different
mouse models provided greater sensitivity and statistical
confidence in selection of differentially expressed genes
allowed us to identify a comprehensive list of genes,
PRGs, from our BMAP microarrays that are consistently
deregulated in these models. We show that many of these
PRGs are most likely expressed in proliferating astrocytes
and microglia in the brains of prion infected mice.
Although a number of cell types are able to propagate pri-
ons it is neuronal cells which sustain the damage which
leads to clinical symptoms and death. A recent study by
Malluci et al showed that the replication of prion in non-
neuronal cells is insufficient to cause damage to PrP-null
neurons suggesting that deregulated genes expressed in
non-neuronal cells are secondary to those involved in
neuronal damage [49]. However, a complimentary study
by Jeffrey et al in which transgenic mice expressing PrPC
only in astrocytes did succumb to disease, albeit following
an extended incubation period, suggests that the mecha-
nisms of cell death are complicated, and not restricted to
a neuronal response [50]. It is possible that different path-
ways leading to cell death are triggered either by the direct
effect of a build up of PrPSc or by an indirect effect trig-
gered by the intra-neuronal replication of PrPSc. The
implementation of gene expression studies in isolated cell
populations to identify pathways triggered in these differ-
ent models will be instrumental in determining the
molecular events that define prion pathogenesis in vivo.
In this report we show a bioinformatic strategy to separate
non-neuronal and neuronal gene expression. Although
many of this core group of genes has been identified in
previous genomic studies of neurodegeneration in
mouse-adapted scrapie, the use of these new bioinformat-
ics tools allows us to gain further insights into the prion
pathobiology. Further work using microdissection strate-
gies and single cell analysis is essential to identify those
genes most important to pathogenesis.
Methods
Biological material
C57BL/6 or VM mice were inoculated intracerebrally with
20 μl of 1% brain homogenate from mice infected with
scrapie strains 22A, ME7, or 79a. At the onset of clinical
symptoms 8 to 10 mice per sample group were sacrificed
and the whole brains used for RNA extraction. An equal
number of age-matched, mock-infected mice (inoculated
with a 1% brain homogenate of either C57BL/6 or VM
mice) were used as controls for each group. Due to the
long time course of infection in mice we stored mouse
brain tissue at -80°C in RNAlater solution (Ambion) until
all experimental time points were completed. All proce-
dures involving live animals were approved by the Cana-
Summary of the genes, pathways and biological processes  that characterize the key events in prion pathogenesis Figure 7
Summary of the genes, pathways and biological processes 
that characterize the key events in prion pathogenesis. Sche-
matic of the postulated molecular and cellular pathogenic 
mechanisms triggered during prion-induced neurodegenera-
tion. Genes in red are those significantly up-regulated during 
disease, while green type indicates down-regulated genes.BMC Genomics 2008, 9:114 http://www.biomedcentral.com/1471-2164/9/114
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dian Science Centre for Human and Animal Health
Animal Care Committee.
Microarray analysis
RNA was isolated from brain tissue by disruption in Trizol
reagent (Invitrogen) and was further purified using RNe-
asy columns (Qiagen) according to the manufacturer's
instructions. A quantity of 10 μg of total RNA was used as
a template for oligo dT primed reverse transcription which
incorporated amino allyl-dUTP (Sigma) into the cDNA.
The remaining RNA template was hydrolyzed and the
cDNA product purified using the QIAquick PCR purifica-
tion system (Qiagen). PCR products were dried down,
then resuspended in 0.1 M Na2CO3 buffer, and incubated
for 1 hour in either an Alexa Fluor555 (AF555) or Alexa
Fluor647 (AF647) mono-functional reactive dye (Molecu-
lar Probes) made up in DMSO. Labelled cDNA was also
purified using QIAquick PCR purification columns.
Array hybridization and scanning
Labelled cDNA was dried down and resuspended in 60 μl
DIG Easy Hyb hybridization buffer (Roche) containing
calf thymus DNA (Sigma) and yeast tRNA (Life Technolo-
gies). The labelled cDNAs were applied to arrays that con-
tained 11,136 cDNAs from the Brain Molecular Anatomy
Project (BMAP). Arrays were constructed in-house as pre-
viously described [2]. Hybridization was performed under
M Series Lifter Slips (Erie Scientific Company) and the
slides incubated in a hybridization chamber at 42°C for
16 hours. Following hybridization lifter slips were
removed and the arrays washed a total of 3 times for 5
minutes each in 1 × SSC, 0.2% SDS then 0.1 × SSC, 0.2%
SDS pre-warmed to 42°C. A final wash in 0.1 × SSC at
room temperature was performed and slides spun to dry.
Spots were quantitated and background signals removed
using Array-Pro® Analyser software (Media Cybernetics,
Inc).
Data were stored and normalized in the GeneTraffic
Microarray Database and Analysis System (Iobion Infor-
matics, La Jolla, CA). The raw data was filtered so that
individual spots had to pass a number of quality criteria
including, minimum intensity levels, minimum signal to
background ratios, and no greater than 10% missing val-
ues for each gene. Genes who passed these criteria were
used for further data analysis. Each slide was then normal-
ized using a linear regression, smoothing algorithm
(Loess best-fit) over individual array sub grids. Log2 ratios
were used for statistical analysis using EDGE (Extraction
of Differential Gene Expression), an open source software
program for the significance analysis of DNA microarray
experiments [51]. Significance calculations are based on
the Optimal Discovery Procedure developed by Storey et
al [51], which estimates the optimal rule for identifying
differentially expressed genes [52,53]. A significance
measure is assigned to each gene P-value cut-off of 0.05
was selected as the significance threshold by which signif-
icantly differentially expressed genes were identified.
Real time PCR
To remove any contaminating genomic DNA from the
RNA template approximately 2 μg of total RNA was
DNase I treated using the DNA-free system (Ambion).
TaqMan® quantitative real-time PCR was performed on
cDNA reverse transcribed from total RNA collected from
brain tissue samples with several TaqMan® Gene Expres-
sion Assays, and all protocols and analysis were followed
as per the manufacturer (Applied Biosystems). Reverse
transcription of 100 ng of total RNA was carried out using
the High Capacity cDNA Reverse Transcription kit. Subse-
quently, 1 μl from each reverse transcription reaction was
assayed in a 20 μl singleplex reaction for real-time quanti-
tation with the PCR 7500 Fast System (Applied Biosys-
tems). Each sample was run in biological triplicate, of
which 3 technical replicates were performed. GAPDH was
used as the endogenous control, and gene expression of
target genes for infected samples were quantitatively
measured relative to those of RNA from mock-infected,
age matched control mice. Relative quantification values
were determined using the 2-ΔΔct method, and expressed as
fold-change in the infected mice versus mock-infected
controls.
Functional analysis of the data set
Annotation of expression data was performed with refer-
ence to a number of sources which include; NIH DAVID
the Gene Ontology Consortium, Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway [54-56]. The Inge-
nuity Pathway Analysis functional analysis tool was also
used to identify the biological functions and/or diseases
that were most significant to the data set. Genes from the
dataset were associated with biological functions and/or
diseases. Fischer's exact test was used to calculate a p-value
determining the probability that each biological function
and/or disease assigned to that data set is due to chance
alone. Canonical pathways were also identified from the
Ingenuity Pathways Analysis library; canonical pathways
that were most significant to the data set were selected.
The significance of the association between the data set
and the canonical pathway was measured in 2 ways: 1) a
ratio of the number of genes from the data set that map to
the pathway divided by the total number of genes that
map to the canonical pathway is displayed. 2) Fischer's
exact test was used to calculate a p-value determining the
probability that the association between the genes in the
dataset and the canonical pathway is explained by chance
alone.BMC Genomics 2008, 9:114 http://www.biomedcentral.com/1471-2164/9/114
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Network generation
Data containing gene identifiers for the PRG genes and
corresponding expression values were uploaded into in
the application. Each gene identifier was mapped to its
corresponding gene object in the Ingenuity Pathways
Knowledge Base. Genes present in this database, called
Focus Genes, were overlaid onto a global molecular net-
work developed from information contained in the Inge-
nuity Pathways Knowledge Base. Networks of these Focus
Genes were then algorithmically generated based on their
connectivity. Functional analysis was performed on these
networks to identify the biological functions and/or dis-
eases that were most significant to the genes in the net-
work. Fischer's exact test was used to calculate a p-value
determining the probability that each biological function
and/or disease assigned to that network is due to chance
alone.
Genes or gene products are represented as nodes, and the
biological relationship between two nodes is represented
as an edge (line). All edges are supported by at least 1 ref-
erence from the literature, from a textbook, or from
canonical information stored in the Ingenuity Pathways
Knowledge Base. Human, mouse, and rat orthologs of a
gene are stored as separate objects in the Ingenuity Path-
ways Knowledge Base, but are represented as a single node
in the network. The intensity of the node color indicates
the degree of up- (red) or down- (green) regulation.
Nodes are displayed using various shapes that represent
the functional class of the gene product. Edges are dis-
played with various labels that describe the nature of the
relationship between the nodes (e.g., P for phosphoryla-
tion, T for transcription).
Accession numbers
The BMAP and Agilent microarray related data were sub-
mitted to Gene Expression Omnibus (GEO) under acces-
sion number: [GSE10310]
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prion protein (PrPSc)
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